

VPA10782/027/001

HuveGuard MMAT suspension for oral suspension for chickens

Variation	Summary	Date
Vet - A1 e)	VNRA - Vet - A1 e) - - Vet - A1 e) Administrative changes - Change in the name or address of a manufacturer or importer of the finished product (including batch release or quality control testing sites)	09/09/26
Vet - F.II.d.2 a)	VRA-S - Vet - F.II.d.2 a) - - Vet - F.II.d.2 a) - Change in test procedure for the finished product - Substantial change to, or replacement of, a biological/ immunological/ immunochemical test method or a method using a biological reagent or replacement of a biological reference preparation not covered by an approved protocol	19/03/26
Vet - F.I.b.2 a)	VRA-S - Vet - F.I.b.2 a) - - Vet - F.I.b.2 a) - Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological active substance	19/03/26
Vet - F.I.a.2 b)	VRA-S - Vet - F.I.a.2 b) - - Vet - F.I.a.2 b) - Changes in the manufacturing process of the active substance - The change refers to a biological / immunological substance or use of a different chemically derived substance in the manufacture of a biological/immunological substance, which may have a significant impact on the quality, safety and efficacy of the medicinal product and is not related to a protocol	23/07/25
Vet - C1	VNRA - Vet - C1 - Change(s) in the name or address or contact details of a qualified person for pharmacovigilance (QPPV) - C1 Changes to the safety, efficacy and pharmacovigilance part of the dossier: Change(s) in the name or address or contact details of a qualified person for pharmacovigilance (QPPV)	10/06/25
Vet - C6	VNRA - Vet - C6 - Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in the Annex to Regulation (EU) 2021/17 - C6 Changes to the safety, efficacy and pharmacovigilance part of the dossier: Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in the Annex to Regulation (EU) 2021/17	10/06/25
Vet - C9	VNRA - Vet - C9 - Editorial changes to SPC, package leaflet or labelling if inclusion in an upcoming procedure is not possible - C9 Changes to the safety, efficacy and pharmacovigilance part of the dossier: Editorial changes to SPC, package leaflet or labelling if inclusion in an upcoming procedure is not possible	13/09/24
Vet - F.II.f.1 a) 5.	VRA-R - Vet - F.II.f.1 a) 5. - a) Extension of the shelf life of	11/04/24

	the finished product 5. Extension of the shelf-life of a biological/immunological medicinal product in accordance with an approved stability protocol. - F.II.f.1 a) 5. Quality Changes -Stability - Change in the shelf-life or storage conditions of the finished product - Extension of the shelf life of the finished product - Extension of the shelf-life of a biological/immunological medicinal product in accordance with an approved stability protocol.	
Vet - F.I.d.1 c)	VRA-R - Vet - F.I.d.1 c) - c) Extension or introduction of a re-test period/storage period supported by real time data - F.I.d.1 c) Quality Changes - Active Substance - Stability -Change in the re-test period/storage period of the active substance where no Ph. Eur. Certificate of Suitability covering the retest period is part of the approved dossier - Extension or introduction of a re-test period/storage period supported by real time data	11/04/24
Vet - G.I.18	VRA-S - Vet - G.I.18 - One-off alignment of the product information with version 9.0 (or the latest version of the QRD templates that are in effect at the time that this one-off variation is submitted) of the QRD templates i.e. major update of the QRD templates in accordance with Regulation (EU) 2019/6, for veterinary medicinal products placed on the market in accordance with Directive 2001/82/EC or Regulation (EC) No 726/2004 - G.I.18 Safety, Efficacy, Pharmacovigilance changes - One-off alignment of the product information with version 9.0 (or the latest version of the QRD templates that are in effect at the time that this one-off variation is submitted) of the QRD templates i.e. major update of the QRD templates in accordance with Regulation (EU) 2019/6, for veterinary medicinal products placed on the market in accordance with Directive 2001/82/EC or Regulation (EC) No 726/2004	11/04/24
Vet - A1 b)	VNRA - Vet - A1 b) - b) Change in the name or address or contact details of a manufacturer or supplier of the active substance, starting material, reagent or intermediate used in the manufacture of the active substance or a quality control testing site (where ecified in the dossier) where no European Pharmacopoeia (Ph. Eur.) Certificate of Suitability (CEP) is part of the approved dossier. - A1 b) Administrativie changes: Change in the name or address or contact details of a manufacturer or supplier of the active substance, starting material, reagent or intermediate used in the manufacture of the active substance or a quality control testing site (where ecified in the dossier) where no European Pharmacopoeia (Ph. Eur.) Certificate of Suitability (CEP) is part of the approved dossier.	07/07/22
B.I.a.2.a	IB - B.I.a.2.a - a) Minor change in the manufacturing process of the active substance - B.I.a.2.a - QUALITY CHANGES - ACTIVE SUBSTANCE - Manufacture - Changes in the manufacturing process of the active substance - Minor change in the manufacturing process of the active substance	20/06/22